

10/536504

JG06 Rec'd PCT/US 25 MAY 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88025

Julia CIANCI, et al.

Appln. No.: National Stage Entry of PCT/AU2003/001588

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: May 25, 2005

Examiner: Unknown

For: NOVEL CHEMICAL COMPOUNDS AND THEIR USE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/536504

JCGC Rec'd PCT/ 25 MAY 2005

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: National Stage Entry of PCT/AU2003/001588
Attorney Docket No.: Q88025

filng a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: May 25, 2005

10/536504
JC06 Rec'd PCT/PTO 25 MAY 2005
MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO				Complete if Known
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>				National Stage Entry of PCT/AU2003/001588
(use as many sheets as necessary)				Confirmation Number Unknown
				Filing Date May 25, 2005
				First Named Inventor Julia CIANCI
				Art Unit Unknown
				Examiner Name
Sheet	1	of	1	Attorney Docket Number Q88025

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 4,347,354		08-31-1982	Martin J. Cron et al
		US 4,020,269		04-26-1977	Kentaro Hiraga et al
		US 3,940,382		02-24-1976	Hamao Umezawa et al
		US 4,024,332		05-17-1977	Brian Richard Fenner et al
		US			

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Nakagawa S et al., "Effect of N-alkylation in kanamycin antibiotics", Microbial Drug Resistance, 1976, pages 269-272	
		Nakagawa S et al, "Aminoglycoside antibiotics. XII. Effect of N-alkylation in kanamycin antibiotics", Journal of Antibiotics, 1978, vol. 31 no. 3, pages 675-680	
		Abe Y et al, "Aminoglycoside antibiotics. XI. Synthesis and activity of 4'-deoxykanamycin B." Journal of Antibiotics, 1977, vol. 30 no. 11, pages 1004-1007	

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.